Page 1 | Search Results | Diabetes Care | American Diabetes Association

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin

Til Stürmer, MD, M. Alison Marquis, MSTAT, Haibo Zhou, PHD, James B. Meigs, MD, Soo Lim, MD, Lawrence Blonde, MD, Eileen MacDonald, MD, Ray Wang, MS, Lisa M. LaVange, PHD, Virginia Pate, MS, John B. Buse, MD

Diabetes Care 2013;36(11):3517–3525

https://doi.org/10.2337/dc13-0263

Published: 15 October 2013

View article titled, Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin

Includes: Supplementary data

Journal Articles

Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

David M. Nathan, MD, John B. Buse, MD, Steven E. Kahn, MB, Heidi Krause-Steinrauf, MS, Mary E. Larkin, MS, Myrlene Staten, MD, Deborah Wexler, MD, John M. Lachin, SCD, the GRADE Study Research Group

Diabetes Care 2013;36(8):2254–2261

https://doi.org/10.2337/dc13-0356

Published: 11 July 2013

View article titled, Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Journal Articles

Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors’ Expert Forum

Itamar Raz, MD, Matthew C. Riddle, MD, Julio Rosenstock, MD, John B. Buse, MD, PHD, Silvio E. Inzucchi, MD, Philip D. Home, DM, DPHIL, Stefano Del Prato, MD, Ele Ferrannini, MD, Juliana C.N. Chan, MD, Lawrence A. Leiter, MD, Derek LeRoith, MD, PHD, Ralph DeFronzo, MD, William T. Cefalu, MD

Diabetes Care 2013;36(6):1779–1788

https://doi.org/10.2337/dc13-0512

Published: 15 May 2013

View article titled, Personalized Management of Hyperglycemia in Type 2 Diabetes: <subtitle>Reflections from a <em>Diabetes Care</em> Editors’ Expert Forum</subtitle>

Includes: Supplementary data

Journal Articles

Diabetes Screening With Hemoglobin A_1c Versus Fasting Plasma Glucose in a Multiethnic Middle-School Cohort

John B. Buse, MD, Francine R. Kaufman, MD, Barbara Linder, MD, Kathryn Hirst, PHD, Laure El ghormli, MS, Steven Willi, MD, for the HEALTHY Study Group

Diabetes Care 2013;36(2):429–435

https://doi.org/10.2337/dc12-0295

Published: 17 January 2013

View article titled, Diabetes Screening With Hemoglobin A<sub>1c</sub> Versus Fasting Plasma Glucose in a Multiethnic Middle-School Cohort

Includes: Supplementary data

Journal Articles

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Silvio E. Inzucchi, MD, Richard M. Bergenstal, MD, John B. Buse, MD, Michaela Diamant, MD, Ele Ferrannini, MD, Michael Nauck, MD, Anne L. Peters, MD, Apostolos Tsapas, MD, Richard Wender, MD, David R. Matthews, MD

Diabetes Care 2012;35(6):1364–1379

https://doi.org/10.2337/dc12-0413

Published: 11 May 2012

View article titled, Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: <subtitle>Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)</subtitle>

Includes: Supplementary data

Journal Articles

Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes

Julio Rosenstock, MD, Sylvia K. Shenouda, PHD, Richard M. Bergenstal, MD, John B. Buse, MD, Leonard C. Glass, MD, Cory R. Heilmann, PHD, Anita Y.M. Kwan, MS, Leigh A. MacConell, PHD, Byron James Hoogwerf, MD

Diabetes Care 2012;35(5):955–958

https://doi.org/10.2337/dc11-1434

Published: 11 April 2012

View article titled, Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes

Includes: Supplementary data

Journal Articles

Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study: Results from the 6-month continuation phase

Richard M. Bergenstal, MD, William V. Tamborlane, MD, Andrew Ahmann, MD, John B. Buse, MD, George Dailey, MD, Stephen N. Davis, MD, Carol Joyce, MD, Bruce A. Perkins, MD, John B. Welsh, MD, Steven M. Willi, MD, Michael A. Wood, MD, for the STAR 3 Study Group

Diabetes Care 2011;34(11):2403–2405

https://doi.org/10.2337/dc11-1248

Published: 15 October 2011

View article titled, Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study: <subtitle>Results from the 6-month continuation phase</subtitle>

Includes: Supplementary data

Journal Articles

The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) Trial: Comparing the durability of lispro mix 75/25 and glargine

John B. Buse, MD, Bruce H.R. Wolffenbuttel, MD, William H. Herman, MD, Stephen Hippler, MD, Sherry A. Martin, MD, Honghua H. Jiang, PHD, Sylvia K. Shenouda, PHD, Jessie L. Fahrbach, MD

Diabetes Care 2011;34(2):249–255

https://doi.org/10.2337/dc10-1701

Published: 20 January 2011

View article titled, The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) Trial: <subtitle>Comparing the durability of lispro mix 75/25 and glargine</subtitle>

Includes: Supplementary data

Journal Articles

Clinical Care Guidelines: Too Much of a Good Thing?

Deepa Kirk, MD, John B. Buse, MD, PHD

Diabetes Care 2010;33(12):2716–2718

https://doi.org/10.2337/dc10-1824

Published: 01 December 2010

View article titled, Clinical Care Guidelines: Too Much of a Good Thing?

Journal Articles

Screening for Diabetes and Prediabetes With Proposed A1C-Based Diagnostic Criteria: Comment on Olson et al.

John B. Buse, MD, PHD

Diabetes Care 2010;33(12):e174

https://doi.org/10.2337/dc10-1720

Published: 01 December 2010

View article titled, Screening for Diabetes and Prediabetes With Proposed A1C-Based Diagnostic Criteria: <subtitle>Comment on Olson et al.</subtitle>

Journal Articles

Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial

Matthew C. Riddle, MD, Walter T. Ambrosius, PHD, David J. Brillon, MD, John B. Buse, MD, PHD, Robert P. Byington, MPH, PHD, Robert M. Cohen, MD, David C. Goff, Jr., MD, PHD, Saul Malozowski, MD, PHD, Karen L. Margolis, MD, MPH, Jeffrey L. Probstfield, MD, Adrian Schnall, MD, Elizabeth R. Seaquist, MD, for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Investigators

Diabetes Care 2010;33(5):983–990

https://doi.org/10.2337/dc09-1278

Published: 01 May 2010

View article titled, Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial

Includes: Supplementary data

Journal Articles

Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents

John B. Buse, MD, PHD, Giorgio Sesti, MD, Wolfgang E. Schmidt, MD, PHD, Eduard Montanya, MD, PHD, Cheng-Tao Chang, PHD, Yizhen Xu, MD, PHD, Lawrence Blonde, MD, Julio Rosenstock, MD, for the Liraglutide Effect Action in Diabetes (LEAD)-6 Study Group

Diabetes Care 2010;33(6):1300–1303

https://doi.org/10.2337/dc09-2260

Published: 23 March 2010

View article titled, Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents

Includes: Supplementary data

Journal Articles

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

John B. Buse, MD, PHD, Daniel J. Drucker, MD, Kristin L. Taylor, PHD, Terri Kim, MS, Brandon Walsh, PHD, Hao Hu, MS, Ken Wilhelm, MD, Michael Trautmann, MD, Larry Z. Shen, PHD, Lisa E. Porter, MD, for the DURATION-1 Study Group

Diabetes Care 2010;33(6):1255–1261

https://doi.org/10.2337/dc09-1914

Published: 09 March 2010

View article titled, DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

Includes: Supplementary data

Journal Articles

Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

Daniel J. Drucker, MD, Steven I. Sherman, MD, Fred S. Gorelick, MD, Richard M. Bergenstal, MD, Robert S. Sherwin, MD, John B. Buse, MD, PHD

Diabetes Care 2010;33(2):428–433

https://doi.org/10.2337/dc09-1499

Published: 01 February 2010

View article titled, Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

Journal Articles

Can We Become Victims of Our Own Success?

John B. Buse, MD, PHD

Diabetes Care 2009;32(11):2140–2141

https://doi.org/10.2337/dc09-1653

Published: 01 November 2009

View article titled, Can We Become Victims of Our Own Success?

Journal Articles

How Do We Define Cure of Diabetes?

John B. Buse, MD, PHD, Sonia Caprio, MD, William T. Cefalu, MD, Antonio Ceriello, MD, Stefano Del Prato, MD, Silvio E. Inzucchi, MD, Sue McLaughlin, BS, RD, CDE, CPT, Gordon L. Phillips, II, MD, R. Paul Robertson, MD, Francesco Rubino, MD, Richard Kahn, PHD, M. Sue Kirkman, MD

Diabetes Care 2009;32(11):2133–2135

https://doi.org/10.2337/dc09-9036

Published: 01 November 2009

View article titled, How Do We Define Cure of Diabetes?

Journal Articles

DURAbility of Basal Versus Lispro Mix 75/25 Insulin Efficacy (DURABLE) Trial 24-Week Results: Safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes

John B. Buse, MD, PHD, Bruce H.R. Wolffenbuttel, MD, PHD, William H. Herman, MD, MPH, Natalie K. Shemonsky, MD, Honghua H. Jiang, PHD, Jessie L. Fahrbach, MD, Jamie L. Scism-Bacon, PHD, Sherry A. Martin, MD

Diabetes Care 2009;32(6):1007–1013

https://doi.org/10.2337/dc08-2117

Published: 31 March 2009

View article titled, DURAbility of Basal Versus Lispro Mix 75/25 Insulin Efficacy (DURABLE) Trial 24-Week Results: <subtitle>Safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes</subtitle>

Includes: Supplementary data

Journal Articles

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

Bernard Zinman, MD, John Gerich, MD, John B. Buse, MD, PHD, Andrew Lewin, MD, Sherwyn Schwartz, MD, Philip Raskin, MD, Paula M. Hale, PHD, Milan Zdravkovic, PHD, Lawrence Blonde, MD, the LEAD-4 Study Investigators

Diabetes Care 2009;32(7):1224–1230

https://doi.org/10.2337/dc08-2124

Published: 16 March 2009

View article titled, Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

Includes: Supplementary data

Journal Articles

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

David M. Nathan, MD, John B. Buse, MD, PHD, Mayer B. Davidson, MD, Ele Ferrannini, MD, Rury R. Holman, FRCP, Robert Sherwin, MD, Bernard Zinman, MD

Diabetes Care 2009;32(1):193–203

https://doi.org/10.2337/dc08-9025

Published: 01 January 2009

View article titled, Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: <subtitle>A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes</subtitle>

Journal Articles

Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: Update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

David M. Nathan, MD, John B. Buse, MD, PHD, Mayer B. Davidson, MD, Ele Ferrannini, MD, Rury R. Holman, FRCP, Robert Sherwin, MD, Bernard Zinman, MD

Diabetes Care 2008;31(1):173–175

https://doi.org/10.2337/dc08-9016

Published: 01 January 2008

View article titled, Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: <subtitle>Update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes</subtitle>

NARROW

Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin

Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors’ Expert Forum

Diabetes Screening With Hemoglobin A_1c Versus Fasting Plasma Glucose in a Multiethnic Middle-School Cohort

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes

Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study: Results from the 6-month continuation phase

The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) Trial: Comparing the durability of lispro mix 75/25 and glargine

Clinical Care Guidelines: Too Much of a Good Thing?

Screening for Diabetes and Prediabetes With Proposed A1C-Based Diagnostic Criteria: Comment on Olson et al.

Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial

Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

Can We Become Victims of Our Own Success?

How Do We Define Cure of Diabetes?

DURAbility of Basal Versus Lispro Mix 75/25 Insulin Efficacy (DURABLE) Trial 24-Week Results: Safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: Update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only